@article{8f58c91f5e354940b592865d413c6160,
title = "Evolution of Next Generation Therapeutics: Past, Present, and Future of Precision Medicines",
author = "Anuradha Ramamoorthy and Karnes, \{Jason H.\} and Richard Finkel and Rebecca Blanchard and Michael Pacanowski",
note = "Funding Information: No funding was received for this work. This Commentary highlights proceedings from the workshop titled “Evolution of Next Generation Therapeutics: Past, Present, and Future of Precision Medicines” at the 2019 American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting in Washington DC. Funding Information: R.B. is an employee and stockholder of CRISPR Therapeutics. R.F. received grant support from the National Institutes of Health (NIH), MDA, SMA Foundation, Ionis Pharmaceuticals, Biogen, Roche, AveXis, Lilly, Sarepta, BMS, Summit, Catabasis, ReveraGen, and Italfaramaco. He is an Advisor to the NIH, SMA Foundation, Cure SMA, SMA REACH UK, SMA Europe, TREAT‐NMD, Ionis, Biogen, Roche, AveXis, Novartis, Biomarin, Catabasis, Mitobridge, Capricor, and Neurogene. He is a DSMB Member of Nationwide CH scAAV9 P1 and Roche Moonfish P1‐2 studies. As an Associate Editor for , M.P. was not involved in the review or decision process for this paper. All other authors declared no competing interests for this work. Clinical and Translational Science ",
year = "2019",
month = nov,
day = "1",
doi = "10.1111/cts.12675",
language = "English (US)",
volume = "12",
pages = "560--563",
journal = "Clinical and Translational Science",
issn = "1752-8054",
publisher = "John Wiley and Sons Inc.",
number = "6",
}